ЗНАЧЕНИЕ НАЦИОНАЛЬНОГО РЕГИСТРА БОЛЬНЫХ АНЦА-АССОЦИИРОВАННЫМИ СИСТЕМНЫМИ ВАСКУ ЛИТАМИ КАК ИННОВАЦИОННОГО ИНСТРУМЕНТА ПЕРСОНИФИЦИРОВАННОЙ ИНДУКЦИОННОЙ И ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ

Системные васкулиты,  ассоциированные с антинейтрофильными цитоплазматическими антителами (АНЦА-СВ), характеризуются  полиорганным поражением, гетерогенностью клинико-иммунологических форм,  разнообразием проявлений и на всех этапах требуют качественного взаимодействия между пациентом и врачом. Основой  успешной  терапии является  рациональное и персонифицированное поддержание тонкого баланса между применением научно обоснованного протокола  лечения,  достаточного для стойкого  подавления активности АНЦА-СВ,  и одновременным сдерживанием риска осложнений лечения.

В ответ на возросшую потребность  в совершенствовании подходов к ведению пациентов с АНЦА-СВ в ФГБНУ  НИИР имени В.А. Насоновой разработан  Национальный регистр больных АНЦА-СВ,  представляющий собой регулярно обновляемую  электронную базу динамического мониторинга больных, который  следует рассматривать как инновационный инструмент  персонифицированной индукционной и поддерживающей терапии,  соответствующий современной концепции «Лечение до достижения цели» (TreattoTarget). Основной  задачей регистра является  стабильное воспроизведение целей терапии АНЦА-СВ,  включая поддержание устойчивой ремиссии, снижение  частоты неблагоприятных реакций  на лечение,  контроль коморбидной патологии, достижение  высокого качества жизни. Дальнейшее развитие Национального регистра больных АНЦА-СВ как федеральной программы  может играть ключевую роль в повышении эффективности здравоохранения больных с редкими  и тяжелыми  заболеваниями, способствовать развитию  информационных и телекоммуникационных медицинских технологий  для обеспечения пациентам с АНЦА-СВ возможности неотложной консультативной и лечебной помощи  в экспертных  центрах, преемственности на разных этапах лечения,  уменьшению фармакоэкономических затрат.

1. Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69:1744-50. doi: 10.1136/ard.2009.119032

2. Scott DG, Watts RA. Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis. 2000 Mar;59(3):161-3. doi: 10.1136/ard.59.3.161

3. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. doi: 10.1136/annrheumdis-2016-209133

4. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545-53. doi: 10.1016/j.ejim.2015.04.022

5. Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-7. doi: 10.1136/annrheumdis-2012- 201531

6. Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306-9. doi: 10.1093/rheumatology/ket445

7. Бекетова ТВ, Александрова ЕН, Новоселова ТМ и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научнопрактическая ревматология. 2014;52(2):147-58 [Beketova TV, Aleksandrova EN, Novoselova TM, et al. Russian experience with using monoclonal antibodies to b-lymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the russian register NORMA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):147-58 (In Russ.)]. doi: 10.14412/1995-4484-2014-147-158

8. Luqmani RA. Treat-to-target in vasculitis: is this a sensible approach? Clin Exp Rheumatol. 2012;30 Suppl 73:149-53.

9. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994 Nov;87(11):671-8.

10. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997 Feb;40(2):371-80. doi: 10.1002/art.1780400222

11. Koutantji M, Harrold E, Lane SE, et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003;49:826-37. doi: 10.1002/art.11471

12. Новик АА, Ионова ТИ. Руководство по исследованию качества жизни в медицине. Москва: ОЛМА-ПРЕСС; 2002. 314 с. [Novik AA, Ionov TI. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine [Guide to the study of quality of life in medicine]. Moscow: Olma-Press; 2002. 314 p.].

13. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605-17. doi: 10.1136/ard.2006.062711

14. Merkel PA, Aydin SZ, Boers M, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol. 2011 Jul;38(7):1480-6. doi: 10.3899/jrheum.110276

15. Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310-7. doi: 10.1136/ard.2008.088096

16. Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46:1615-6. doi: 10.1093/rheumatology/kem146a

17. Suka M, Hayashi T, Kobayashi S, et al. Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAAV study. Mod Rheumatol. 2012 Nov;22(6):877-84. doi: 10.1007/s10165-012-0602-4

18. Alexander DS, Hogan SL, Jordan JM, et al. The relationship between peer support, medication adherence, and quality of life among patients with vasculitis. Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S185-6. Epub 2015 May 26.

19. Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2011 Jul;63(7):1055-61. doi: 10.1002/acr.20471

20. Allen SD, Harvey CJ. Imaging of Wegener’s granulomatosis. Br J Radiol. 2007 Sep;80(957):757-65. doi: 10.1259/bjr/34705892

21. Murphy JM, Balan KK, Toms A, et al. Radiolabeled leucocyte imaging in diffuse granulomatous involvement of the meninges in Wegener’s granulomatosis: scintigraphic findings and their role in monitoring treatment response to specific immunotherapy (humanized monoclonal antilymphocyte antibodies). AJNR Am J Neuroradiol. 2000;21(8):1460-520.

22. Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCAassociated vasculitis – a meta-analysis. Rheumatology (Oxford). Jan;51(1):100-9. doi: 10.1093/rheumatology/ker280

23. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000 Sep;43(9):2025-33. doi: 10.1002/1529-0131(200009)43:9<2025::AIDANR13>3.0.CO;2-O

24. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 2004 Apr 15;51(2):269-73. doi: 10.1002/art.20234

25. Stegeman C, Tervaert J, Sluiter W, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120:12-7. doi: 10.7326/0003-4819-120-1-199401010-00003

26. Guillevin L, Cordier J, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997;40:2187-98. doi: 10.1002/art.1780401213

27. Семенкова ЕН. Системные некротизирующие васкулиты. Москва: Русский врач; 2001. 96 с. [Semenkova EN. Sistemnye nekrotiziruyushchie vaskulity [Systemic necrotizing vasculitis]. Moscow: Russian doctor; 2001. 96 p.].

28. Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. A randomized trial. Ann Intern Med. 2009;150:670-80. doi: 10.7326/0003-4819-150-10-200905190-00004

29. Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012; 50(6):19-28 [Beketova TV. Granulomatosis with polyangiitis, which is pathogenetically associated with antineutrophil cytoplasmic antibodies: clinical features. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(6):19-28 (In Russ.)]. doi: 10.14412/1995-4484-2012-1288

30. Flossmann O, Berden A, de Groot K, et al.; European Vasculitis Study Group. Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis. 2011 Mar;70(3):488-94. doi: 10.1136/ard.2010.137778

31. Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology (Oxford). 2011 Apr;50(4):697-702. doi: 10.1093/rheumatology/keq351

32. Ollenschlä ger G, Kirchner H, Fiene М. Leitlinien in der Medizin-scheitern sie an der praktischen Umsetzung? Der Internist. 2001;42(4):473-83.

33. Raimundo K, Farr AM, Kim G, Duna G. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol. 2015;42(12):2383-91. doi: 10.3899/jrheum.150479

34. Jones RB, Tervaert JW, Hauser T, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCAassociated renal vasculitis. N Engl J Med. 2010;363(3):211-20. doi: 10.1056/NEJMoa0909169

35. Stone JH, Merkel PA, Spiera R, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32. doi: 10.1056/NEJMoa0909905

36. Guerry M-J, Brogan P, Bruce I, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibodyassociated vasculitis. Rheumatology. 2012;51:634-43. doi: 10.1093/rheumatology/ker150

37. Langford С. Cyclophosphamide as induction therapy for Wegener’s granulomatosis and microscopic polyangiitis. Clin Exp Immunol. 2011 May;164 Suppl 1:31-4. doi: 10.1111/j.1365-2249.2011.04364.x

38. Silva-Fernandez L, Loza E, Martinez-Taboada VM, et al.; Systemic Autoimmune Diseases Study Group of the Spanish Society for Rheumatology (EAS-SER). Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum. 2014 Feb;43(4):542-57. doi: 10.1016/j.semarthrit.2013.07.010. Epub 2013 Aug 24.

39. Donvik К, Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheum Int. 2009;31:89-91. doi: 10.1007/s00296-009-1146-6

40. Cartin-Ceba R, Keogh K, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26:2865-71. doi: 10.1093/ndt/gfq852

41. Kronbichler A, Jayne DR. Con: Should all patients with antineutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? Nephrol Dial Transplant. 2015 Jul;30(7):1075-81. doi: 10.1093/ndt/gfv216

42. Timlin H, Lee SM, Manno RL, et al. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Semin Arthritis Rheum. 2015 Aug;45(1):67-9. doi: 10.1016/j.semarthrit.2015.02.005

43. Pagnoux C, Hogan S, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18. doi: 10.1002/art.23800

44. Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015 Jul;54(7):1153-60. doi: 10.1093/rheumatology/keu452

45. Kartin-Seba R, Goldbin J, Keoch KA, et al. Rituximab for emmission, induction and maintenance in ANCA-associated vasculitis: a single centered 10-year experience in 108 patients. Arthritis Rheum. 2010;62 Suppl 10:680.

46. Latimer NR, Carroll C, Wong R, et al. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal. Pharmacoeconomics. 2014 Dec;32(12):1171-83. doi: 10.1007/s40273-014-0189-z

47. Gregersen JW, Chaudhry A, Jayne DR, et al. Rituximab for ANCA-associated vasculitis in the setting of severe infection. Scand J Rheumatol. 2013;42(3):207-10. doi: 10.3109/03009742.2012.739638

48. Bomback AS, Appel GB, Radhakrishnan J, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79:757-64. doi: 10.1038/ki.2010.489

49. Van Oers MH, van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular nonHodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853-8. doi: 10.1200/JCO.2009.26.5827

50. Weidner S, Geuss S, Hafezi-Rachti S, et al. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19:1403-11. doi: 10.1093/ndt/gfh161

51. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44. doi: 10.1056/NEJMoa020286

52. Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471-81. doi: 10.1093/rheumatology/keu366

53. Turner-Stokes T, Sandhu E, Pepper RJ, et al. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology (Oxford). 2014 Aug;53(8):1395-403. doi: 10.1093/rheumatology/ket489

54. Exley AR, Bacon PA, Luqmani RA, et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol. 1998;37:57-63. doi: 10.1093/rheumatology/37.1.57

55. Talar-Williams C, Hijazi Y, Walther M, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477-84. doi: 10.7326/0003-4819-124-5-199603010-00003

56. Hoffman G, Kerr G, Leavitt R, et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med. 1992;116:488-98. doi: 10.7326/0003-4819-116-6-488

57. Стрижаков ЛА, Моисеев СВ, Коган ЕА и др. Поражение сердца при системных васкулитах: патогенетические звенья, значение факторов риска развития сердечнососудистых осложнений и диагностика. Терапевтический архив. 2014;12(2):35-42 [Strizhakov LA, Moiseev SV, Kogan EA, et al. Heart disorders in systemic vasculitis: Pathogenetic links, importance of risk factors for cardiovascular complications and diagnostics. Terapevticheskiy Arkhiv. 2014;12(2):35-42 (In Russ.)].

58. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-96. doi: 10.1002/acr.20433

59. Little MA, Nightingale P, Verburgh CA, et al.; European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69:1036-43. doi: 10.1136/ard.2009.109389

60. Bosch X, Guilabert А, Espinosa G, et al. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JAMA. 2007;298:655-69. doi: 10.1001/jama.298.6.655

61. Le Guenno G, Mahr A, Pagnoux C, et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 2011;63:1435-45. doi: 10.1002/art.30296

62. Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307-11. doi: 10.1136/ard.2003.019125

63. Monach P, Arnold L, Merkel P. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62:9-21. doi: 10.1002/art.25061

64. Данилов ДС. Терапевтическое сотрудничество (комплаенс): содержание понятия, механизмы формирования и методы оптимизации. Неврология, нейропсихиатрия, психосоматика. 2014;6(2):4-12 [Danilov D. Therapeutic collaboration (compliance): Content of the definition, mechanisms of formation, and methods of optimization. Nevrologiya, Neyropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2):4-12 (In Russ.)]. doi: 10.14412/2074-2711-2014-2-4-12

65. Carpenter DM, Kadis JA, Devellis RF, et al. The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission. J Rheumatol. 2011;38(4):709-15. doi: 10.3899/jrheum.100808

66. Pepper JK, Carpenter DM, DeVellis RF. Does adherencerelated support from physicians and partners predict medication adherence for vasculitis patients? J Behav Med. 2012;35(2):115-23. doi: 10.1007/s10865-012-9405-5

67. Carpenter DM, Hogan SL, Devellis RF. Predictors of medication non-adherence for vasculitis patients. Clin Rheumatol. 2013 May;32(5):649-57. doi: 10.1007/s10067-013-2164-z

68. Park DC, Hertzog C, Leventhal H, et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc. 1999;47(2):172-83. doi: 10.1111/j.1532-5415.1999.tb04575.x

69. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509-10. doi: 10.1001/archinte.1990.00390190143023

70. McKinney EF, Lyons PA, Carr EJ, et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med. 2010;16(5):586-91, 1p following 591. doi: 10.1038/nm.2130